China’s not the only country with unreliable COVID-19 data

China is currently facing a massive COVID-19 surge, after ending many of its stringent “zero COVID” policies in December. Some estimates suggest that the country is experiencing over a million new cases each day, and widespread travel over the Lunar New Year later this month will likely prolong the surge.

Among U.S. media outlets covering the situation, a common topic is China’s lack of reliable COVID-19 data. For example: “The country no longer tallies asymptomatic infections or reliably reports COVID deaths—employing not the distortion of statistics but their omission,” writes Dhruv Khullar in The New Yorker.

Articles like Khullar’s accurately describe how difficult it is to understand the scale of COVID-19’s impact on a country without accurate data. But they fail to explain that this is far from a uniquely Chinese problem. In fact, many of the same claims that writers and health experts have made about China could also apply to the U.S., albeit on a different scale.

Some examples:

  • Without widespread PCR testing, officially-reported case counts are likely significant underestimates of true infections.
  • Public health agencies are no longer doing widespread contact tracing or attempting to track asymptomatic cases.
  • Official death statistics are also likely underestimates, due to errors and omissions on death certificates.
  • Unchecked spread of the virus could contribute to the development of new variants that evade prior infections and/or vaccinations, but such variants will be hard to quickly identify due to low testing rates.

This Twitter thread, from the writer and podcast host Artie Vierkant, shows the similarities pretty clearly:

Don’t get me wrong—the current surge in China is an immense tragedy. But we can’t talk about it in a vacuum, or ignore the very similar problems plaguing the U.S. and many other countries. Poor COVID-19 data is, unfortunately, a global issue right now.

Sign up for the COVID Data Dispatch newsletter

More international data

Data implications of China ending its zero-COVID policies
China has rolled back some of its most rigorous COVID-19 safety policies, essentially moving away from its “zero COVID” strategy, following recent protests. I am no expert on China’s political or health policies here, but I did want to share …
How testing international travelers helps the CDC keep tabs on new variants
Last month, the CDC started publishing data from a surveillance program focused on international travelers coming into the U.S. I talked to bioinformatics experts involved with the program to learn more about how it works.
Russia’s invasion of Ukraine has COVID-19 impacts
When Russian troops began attacking Ukraine, the country was just recovering from its worst COVID-19 surge of the pandemic. To state the terrifying obvious: war makes it much harder to control a pandemic.
We failed to vaccinate the world in 2021; will 2022 be more successful?
In January, COVAX set a goal that many global health advocates considered modest: delivering 2.3 billion vaccine doses to low- and middle-income countries by the end of 2021. is saying it’ll deliver just 800 million vaccine doses by the end …
Omicron variant: What we know, what we don’t, and why not to panic (yet)
On Thanksgiving, my Twitter feed was dominated not by food photos, but by news of a novel coronavirus variant identified in South Africa earlier this week. While the variant—now called Omicron, or B.1.1.529—likely didn’t originate in South Africa, data from …
First COVID-19 antiviral pill gains authorization
This week, an antiviral pill for COVID-19 was authorized in the U.K. The drug, made by American pharmaceutical company Merck, is the first COVID-19 treatment in pill form to gain approval by any regulatory agency.

Leave a Reply